Disparities in Breast Cancer Survival in the United States (2001-2009): Findings from the CONCORD-2 Study
Overview
Affiliations
Background: Reducing breast cancer incidence and achieving equity in breast cancer outcomes remains a priority for public health practitioners, health care providers, policy makers, and health advocates. Monitoring breast cancer survival can help evaluate the effectiveness of health services, quantify inequities in outcomes between states or population subgroups, and inform efforts to improve the effectiveness of cancer management and treatment.
Methods: We analyzed breast cancer survival using individual patient records from 37 statewide registries that participated in the CONCORD-2 study, covering approximately 80% of the US population. Females were diagnosed between 2001 and 2009 and were followed through December 31, 2009. Age-standardized net survival at 1 year, 3 years, and 5 years after diagnosis was estimated by state, race (white, black), stage at diagnosis, and calendar period (2001-2003 and 2004-2009).
Results: Overall, 5-year breast cancer net survival was very high (88.2%). Survival remained remarkably high from 2001 through 2009. Between 2001 and 2003, survival was 89.1% for white females and 76.9% for black females. Between 2004 and 2009, survival was 89.6% for white females and 78.4% for black females.
Conclusions: Breast cancer survival was more than 10 percentage points lower for black females than for white females, and this difference persisted over time. Reducing racial disparities in survival remains a challenge that requires broad, coordinated efforts at the federal, state, and local levels. Monitoring trends in breast cancer survival can highlight populations in need of improved cancer management and treatment. Cancer 2017;123:5100-18. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Comparison of disease free survival in breast cancer molecular subtypes.
Esmati M, Monfaredi F, Vakili Sadeghi M, Ranaii M, Ghorbani H, Sedaghat S Caspian J Intern Med. 2024; 16(1):141-150.
PMID: 39619759 PMC: 11607120. DOI: 10.22088/cjim.16.1.141.
Lymphatic pain in breast cancer survivors: An overview of the current evidence and recommendations.
Qiu J, Rosemary Fu M, Finlayson C, Tilley C, Payo R, Korth S Women Child Nurs. 2024; 2(2):33-38.
PMID: 39421196 PMC: 11486487. DOI: 10.1016/j.wcn.2024.04.001.
High-value breast cancer care within resource limitations.
Verhoeven D, Siesling S, Allemani C, Roy P, Travado L, Bhoo-Pathy N Oncologist. 2024; 29(7):e899-e909.
PMID: 38780115 PMC: 11224985. DOI: 10.1093/oncolo/oyae080.
Breast Cancer in Young Women: Is It Different? A Single-Center Retrospective Cohort Study.
Abulkhair O, Omair A, Makanjuola D, Al Zaid M, Al Riyees L, Abdelhafiez N Clin Med Insights Oncol. 2024; 18:11795549241228235.
PMID: 38380225 PMC: 10878213. DOI: 10.1177/11795549241228235.
Long noncoding RNA SNHG1 promotes breast cancer progression by regulating the miR-641/RRS1 axis.
Deng L, Wang J, Song J, Wu Q, Gong Z, Song J Sci Rep. 2024; 14(1):3265.
PMID: 38331968 PMC: 10853250. DOI: 10.1038/s41598-024-52953-0.